Intervention in autoimmune diabetes by targeting the gut immune system

International Journal of Immunopharmacology

Volumn 19, Issue 9-10, 1997, Pages 573-577

  Bellmann, Kerstin ^a   Kolb, Hubert ^a   Hartmann, Bettina ^a   Rothe, Helga ^a   Rowsell, Paul ^b   Rastegar, Shila ^b   Burghardt, Karolina ^b   Scott, F W ^b  

^a HEINRICH HEINE UNIVERSITY   (Germany)

^b HEALTH CANADA   (Canada)

Author keywords

BB rat; Diabetes; NOD mouse; OM 89; Oral tolerance; Th1 Th2 balance

Indexed keywords

BACTERIUM LIPOPOLYSACCHARIDE; OM 89;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIGEN PRESENTATION; AUTOIMMUNITY; CONFERENCE PAPER; DESENSITIZATION; DOSE RESPONSE; DRUG EFFECT; HELPER CELL; IMMUNOLOGICAL TOLERANCE; IMMUNOREGULATION; INSULIN DEPENDENT DIABETES MELLITUS; INSULIN TREATMENT; INTESTINE LYMPHATIC TISSUE; MACROPHAGE FUNCTION; NONHUMAN; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; RAT; T LYMPHOCYTE ACTIVATION; TARGET ORGAN;

ADJUVANTS, IMMUNOLOGIC; ADMINISTRATION, ORAL; ANIMALS; ANTIGENS, BACTERIAL; DIABETES MELLITUS, TYPE 1; DIGESTIVE SYSTEM; DISEASE MODELS, ANIMAL; HUMANS; IMMUNE TOLERANCE; IMMUNITY, MUCOSAL; ISLETS OF LANGERHANS; MACROPHAGES; MICE; MICE, INBRED NOD; RATS; RATS, INBRED BB; TH1 CELLS; TH2 CELLS;

EID: 0031224939     PISSN: 01920561     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0192-0561(97)00052-0     Document Type: Conference Paper

References (24)

1. Bach, J. -F. (1994) Insulin-dependent diabetes mellitus as an autoimmune disease. Endocrine Rev., 15, 516-542.
2. Friedman, A. & Weiner, H. L. (1994) Induction of anergy or active suppression following oral tolerance is determined by antigen dosage. Proc. natl. Acad. Sci. U.S.A., 91, 6688-6692.
3. Fukaura, H., Kent, S. C., Pietrusewicz, M. J., Khoury, S. J., Weiner, H. L., Hafler, D. A. (1996) Induction of circulating myelin basic protein and proteolipid protein-specific transforming growth factor-1-secreting Th3 T cells by oral administration of myelin in multiple sclerosis patients. J. Clin. Invest., 98, 70-77.
4. Hartmann, B., Bellmann, K., Ghica, I., Kleemann, R. & Kolb, H. (1997) Oral insulin for diabetes prevention in NOD mice: potentiation by enhancing Thr cytokine expression in the gut through bacterial adjuvant. Diabetologia, 40, 902-909.
5. Lampeter, E. F., Signore, A., Gale, E. A. M. & Pozzilli, P. (1989) Lessons from the NOD mouse for the pathogenesis and immunotherapy of human type I (insulin dependent) diabetes mellitus. Diabetologia, 32, 703-708.
6. Kiesel, U. (1994) Prevention of diabetes in BB rats by an E. coli extract (OM-89). Int. J, Immunopathol. Pharmacol., 7, 193-199.
7. Kolb, H., Wörz-Pagenstert, U., Kleemann, R., Rothe, H., Rowsell, P. & Scott, F. W. (1996) Cytokine gene expression in the BB rat pancreas: natural course and impact of bacterial vaccines. Diabetologia, 39, 1448-1454.
8. Kolb, H., Bellmann, K., Rastegar, S., Lee P. & Scott, F. W. Oral insulin administration in diabetes prone BB rats may exacerbate disease development. Submitted.
9. Kröncke, K. -D., Kolb-Bachofen, V., Berschick, B., Burkart, V. & Kolb, H. (1991) Activated macrophages kill pancreatic syngeneic islet cells via arginine-dependent nitric oxide generation. Biochem. biophys. Res. Commun., 175, 752-758.
10. Leiter, E. H., Prochazka, M. & Coleman, D. L. (1987) The non-obese diabetic (NOD) mouse. Am. J. Pathol., 128, 380-391.
11. Quin, H. -Y., Suarez, W. L., Parfrey, N., Power, R. F. & Rabinovitch, A. (1992) Mechanisms of complete Freund's adjuvant protection against diabetes in BB rats: induction of non-specific suppressor cells. Autoimmunity, 12, 193-199.
12. Rabinovitch, A. (1994) Immunoregulatory and cytokine imbalances in the pathogenesis of IDDM-therapeutic intervention by immunostimulation?. Diabetes, 43, 613-621.
13. Rossini, A., Mordes, J. P. & Greiner, D. L. (1989) The pathogenesis of autoimmune diabetes mellitus. Curr. opin. Immunol., 2, 598-603.
14. Rothe, H., Faust, A., Schade, U., Kleemann, R., Bosse, G., Hibino, T., Martin, S. & Kolb, H. (1994) Cyclophosphamide treatment of female non-obese diabetic mice causes enhanced expression of inducible nitric oxide synthase and interferon-gamma, but not of interleukin-4. Diabetologia, 37, 1154-1158.
15. Rothe, H., Jenkins, N. A., Copeland, N. G. & Kolb, H. (1997) Active stage of autoimmune diabetes is associated with the expression of a novel cytokine, IGIF, which is located near IDD2. J. Clin. Invest., 99, 469-474.
16. Rothe, H. & Kolb, H. Strategies of protection from nitric oxide toxicity in islet inflammation. Submitted.
17. Rothe, H., Öngeren, C., Martin, S. & Kolb, H. (1994) Abnormal TNFα production in diabetes-prone BB rats: enhanced TNFα expression and defective PGE2 feedback inhibition. Immunology, 81, 407.
18. Sadelein, M. W. J., Quin, H. -Y., Sumoski, W., Parfrey, N., Singh, B. & Rabinovitch, A. (1990) Prevention of diabetes in the BB rat by early immunotherapy using Freund's adjuvant. J. Autoimmun., 3, 671-680.
19. Satoh, J., Shintani, S., Oya, K., Tanaka, S. -I., Nobunaga, T., Toyota, T. & Goto, Y. (1988) Involvement of dendritic cells in early insulitis of BB rats. J. Autoimmun., 5, 571-579.
20. Strober, W., Kelsall, B., Fuss, I., Marth, T., Ludviksson, B., Ehrhardt, R. & Neurath, M. (1997) Reciprocal IFN-γ and TGF-β responses regulate the occurrence of mucosal inflammation. Immunol. Today, 18, 61-64.
21. Unglaub, R., Maxeiner, B., Thoma, B., Pfizenmeier, K. & Scheurich, P. (1987) Downregulation of tumor necrosis factor sensitivity via modulation of TNF binding capacity by protein kinase C activators. J. exp. Med., 166, 1788-1797.
22. Zhang, X., Giangreco, L., Broome, H. E., Dargan, C. M. & Swain, S. L. (1995) Control of CD4 effector fate: transforming growth factor β1 and Interleukin 2 synergize to prevent apoptosis and promote effector expansion. J. exp. Med., 182, 699-709.
23. Zhang, Z. & Michael, J. G. (1990) Orally inducible unresponsiveness is abrogated by IFN-γ treatment. J. Immunol., 144, 4163-4165.
24. Ziegler-Heitbrock, H. W. L. (1995) Molecular mechanism in tolerance to lipopolysaccharide. J. Inflamm., 45, 13-26.